Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel Free SANA Stock Alerts

Sana Biotechnology (SANA) Financials

Sana Biotechnology logo
$4.10 +0.32 (+8.47%)
Closing price 04:00 PM Eastern
Extended Trading
$4.06 -0.04 (-1.07%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Sana Biotechnology

Annual Income Statements for Sana Biotechnology

This table shows Sana Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -131 -285 -356 -269 -283 -267 -244
Consolidated Net Income / (Loss)		 -131 -285 -356 -269 -283 -267 -244
Net Income / (Loss) Continuing Operations		 -131 -285 -356 -269 -283 -267 -244
Total Pre-Tax Income 		-138 -285 -356 -269 -283 -267 -246
Total Operating Income		 -141 -286 -357 -273 -293 -273 -250
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 141 286 357 273 293 273 250
Selling, General & Admin Expense		 22 28 50 72 73 64 44
Research & Development Expense		 119 258 306 201 213 207 161
Impairment Charge		 - - - - 7.01 1.89 45
Total Other Income / (Expense), net		 2.83 0.84 0.98 3.09 9.89 5.96 3.85
Interest & Investment Income		 2.86 0.75 0.68 3.76 9.94 10 3.85
Other Gains / (Losses), net		 - - - - - - 2.31
Basic Earnings per Share		 ($26.68) ($21.92) ($2.14) ($1.43) ($1.46) ($1.16) ($0.96)
Weighted Average Basic Shares Outstanding		 4.90M 13.01M 166.43M 188.34M 194.54M 230.89M 253.23M
Diluted Earnings per Share		 ($26.68) ($21.92) ($2.14) ($1.43) ($1.46) ($1.16) ($0.96)
Weighted Average Diluted Shares Outstanding		 4.90M 13.01M 166.43M 188.34M 194.54M 230.89M 253.23M
Weighted Average Basic & Diluted Shares Outstanding		 4.90M 13.01M 166.43M 191.36M 220.45M 225.02M 266.87M

Quarterly Income Statements for Sana Biotechnology

This table shows Sana Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47 -64
Consolidated Net Income / (Loss)		 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47 -64
Net Income / (Loss) Continuing Operations		 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47 -64
Total Pre-Tax Income 		-88 -108 -50 -60 -49 -49 -94 -42 -61 -47 -64
Total Operating Income		 -91 -111 -49 -62 -51 -51 -95 -44 -61 -49 -65
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 91 111 49 62 51 51 95 44 61 49 65
Selling, General & Admin Expense		 21 16 16 14 17 11 10 10 12 11 11
Research & Development Expense		 70 94 33 48 34 39 40 33 49 37 55
Impairment Charge		 - - 0.00 0.00 - 0.00 45 0.00 - 0.00 0.00
Total Other Income / (Expense), net		 2.46 3.03 -0.92 1.84 1.80 1.24 1.18 1.36 0.07 1.40 1.79
Interest & Investment Income		 2.73 3.03 3.20 2.58 1.66 0.99 0.58 1.00 1.28 0.95 1.13
Other Income / (Expense), net		 - - -4.12 -0.74 0.14 0.25 0.60 0.36 - 0.45 0.66
Basic Earnings per Share		 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21) ($0.39) ($0.16) ($0.20) ($0.17) ($0.22)
Weighted Average Basic Shares Outstanding		 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M 238.41M 260.49M 253.23M 276.86M 295.67M
Diluted Earnings per Share		 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21) ($0.39) ($0.16) ($0.20) ($0.17) ($0.22)
Weighted Average Diluted Shares Outstanding		 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M 238.41M 260.49M 253.23M 276.86M 295.67M
Weighted Average Basic & Diluted Shares Outstanding		 220.45M 221.50M 222.47M 223.27M 225.02M 225.56M 237.81M 266.37M 266.87M 278.29M 299.36M

Annual Cash Flow Statements for Sana Biotechnology

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 50 45 135 -75 -50 -5.95 -55
Net Cash From Operating Activities		 -86 -138 -251 -290 -254 -223 -144
Net Cash From Continuing Operating Activities		 -86 -138 -251 -290 -254 -223 -144
Net Income / (Loss) Continuing Operations		 -131 -285 -356 -269 -283 -267 -244
Consolidated Net Income / (Loss)		 -131 -285 -356 -269 -283 -267 -244
Depreciation Expense		 1.83 5.92 11 16 18 16 13
Non-Cash Adjustments To Reconcile Net Income		 21 10 26 41 43 38 68
Changes in Operating Assets and Liabilities, net		 23 131 68 -77 -30 -10 19
Net Cash From Investing Activities		 -88 -253 -246 211 172 17 -40
Net Cash From Continuing Investing Activities		 -88 -253 -246 211 172 17 -40
Purchase of Property, Plant & Equipment		 -26 -24 -30 -21 -20 -33 -0.94
Purchase of Investments		 -142 -387 -491 -79 -158 -226 -87
Sale of Property, Plant & Equipment		 - - - - 0.00 0.00 1.43
Sale and/or Maturity of Investments		 83 159 280 310 350 277 47
Net Cash From Financing Activities		 224 436 632 4.91 32 200 129
Net Cash From Continuing Financing Activities		 224 436 632 4.91 32 200 129
Issuance of Common Equity		 0.00 0.00 632 4.91 32 192 129
Other Financing Activities, net		 0.00 0.15 0.00 0.00 0.00 7.74 -0.35

Quarterly Cash Flow Statements for Sana Biotechnology

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -35 44 -42 -7.96 0.57 -31 -25 32 -31 12 -27
Net Cash From Operating Activities		 -52 -66 -59 -52 -47 -49 -33 -29 -33 -37 -33
Net Cash From Continuing Operating Activities		 -52 -66 -59 -52 -47 -49 -33 -29 -33 -37 -33
Net Income / (Loss) Continuing Operations		 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47 -64
Consolidated Net Income / (Loss)		 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47 -64
Depreciation Expense		 11 3.75 3.90 4.06 5.69 3.65 2.86 3.19 3.05 2.39 2.23
Non-Cash Adjustments To Reconcile Net Income		 7.82 13 13 9.89 5.39 5.98 51 5.71 5.63 5.52 3.58
Changes in Operating Assets and Liabilities, net		 17 25 -26 -5.84 -9.18 -8.90 6.90 3.82 18 1.93 25
Net Cash From Investing Activities		 15 -77 5.82 42 47 17 7.68 -48 -16 49 -88
Net Cash From Continuing Investing Activities		 15 -77 5.82 42 47 17 7.68 -48 -16 49 -88
Purchase of Property, Plant & Equipment		 -14 -16 -13 -4.09 -0.44 -0.14 0.11 -0.04 -0.87 -0.29 -1.62
Purchase of Investments		 -26 -114 -63 -36 -13 -1.68 - -50 -36 -5.59 -102
Sale of Property, Plant & Equipment		 - 0.00 - - - 0.25 0.38 0.14 0.66 0.25 0.02
Sale and/or Maturity of Investments		 55 53 81 82 61 18 7.19 1.41 20 55 16
Net Cash From Financing Activities		 1.72 186 11 2.08 0.64 0.98 0.56 110 18 -0.13 94
Net Cash From Continuing Financing Activities		 1.72 186 11 2.08 0.64 1.07 0.59 109 18 -0.04 93
Issuance of Common Equity		 1.72 186 3.00 1.91 0.70 1.13 0.59 110 18 0.06 94

Annual Balance Sheets for Sana Biotechnology

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 730 1,129 823 565 501 417
Total Current Assets		 384 558 444 214 161 149
Cash & Equivalents		 125 253 177 134 128 72
Restricted Cash		 - 0.00 6.10 3.83 3.83 4.20
Short-Term Investments		 253 298 247 72 25 67
Prepaid Expenses		 6.20 7.11 14 4.49 4.48 6.10
Plant, Property, & Equipment, net		 47 65 67 71 77 27
Total Noncurrent Assets		 299 506 311 281 263 241
Goodwill		 141 141 141 141 141 141
Intangible Assets		 59 59 59 59 59 59
Other Noncurrent Operating Assets		 66 101 101 81 63 41
Total Liabilities & Shareholders' Equity		 730 1,129 823 565 501 417
Total Liabilities		 299 401 323 278 251 256
Total Current Liabilities		 31 99 112 64 45 79
Short-Term Debt		 - 51 55 0.00 0.00 40
Accounts Payable		 2.25 2.22 2.86 4.11 5.21 1.67
Accrued Expenses		 9.47 10 15 23 13 8.68
Current Employee Benefit Liabilities		 16 21 26 24 14 13
Other Current Liabilities		 3.71 14 12 13 13 15
Total Noncurrent Liabilities		 267 302 212 213 205 177
Capital Lease Obligations		 - 102 96 91 82 64
Other Noncurrent Operating Liabilities		 267 200 116 122 123 113
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -421 729 499 288 251 161
Total Preferred & Common Equity		 -421 729 499 288 251 161
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -421 729 499 288 251 161
Common Stock		 8.22 1,515 1,558 1,626 1,855 2,010
Retained Earnings		 -429 -785 -1,055 -1,338 -1,605 -1,849
Accumulated Other Comprehensive Income / (Loss)		 0.03 -1.37 -4.33 -0.06 0.01 0.03

Quarterly Balance Sheets for Sana Biotechnology

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 747 707 631 681 619 559 445 362 435 374 432
Total Current Assets		 370 339 280 321 263 210 113 83 162 112 171
Cash & Equivalents		 160 174 168 177 135 127 96 71 103 84 57
Restricted Cash		 6.10 6.10 3.83 3.83 3.83 3.83 4.20 4.20 4.20 4.20 4.20
Short-Term Investments		 189 152 100 134 117 72 8.57 1.40 50 17 103
Prepaid Expenses		 15 6.61 7.12 6.35 7.98 7.31 3.84 5.63 4.51 6.36 5.94
Plant, Property, & Equipment, net		 64 63 68 82 86 83 74 33 30 26 25
Total Noncurrent Assets		 313 306 284 278 269 266 259 246 244 236 236
Goodwill		 141 141 141 141 141 141 141 141 141 141 141
Intangible Assets		 59 59 59 59 59 59 59 59 59 59 59
Other Noncurrent Operating Assets		 103 106 84 79 69 67 59 46 44 36 36
Total Liabilities & Shareholders' Equity		 747 707 631 681 619 559 445 362 435 374 432
Total Liabilities		 319 352 266 306 279 267 236 239 240 254 277
Total Current Liabilities		 103 112 67 53 51 47 33 33 36 86 124
Short-Term Debt		 57 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 54 91
Accounts Payable		 2.33 3.09 9.93 6.10 3.82 2.99 0.99 2.27 1.86 2.12 1.36
Accrued Expenses		 13 18 19 20 21 15 9.81 7.93 7.99 8.12 8.23
Current Employee Benefit Liabilities		 17 20 24 14 16 18 9.35 9.41 11 7.58 8.84
Other Current Liabilities		 13 13 13 13 10.00 11 13 14 14 15 15
Total Noncurrent Liabilities		 216 240 199 253 228 220 203 206 205 168 153
Capital Lease Obligations		 102 100 83 93 89 85 78 72 68 60 59
Other Noncurrent Operating Liabilities		 114 140 116 160 140 134 125 134 137 108 94
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 428 355 366 375 340 292 209 123 195 119 155
Total Preferred & Common Equity		 428 355 366 375 340 292 209 123 195 119 155
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 428 355 366 375 340 292 209 123 195 119 155
Common Stock		 1,567 1,607 1,616 1,821 1,836 1,848 1,863 1,871 1,985 2,015 2,114
Retained Earnings		 -1,137 -1,251 -1,250 -1,446 -1,496 -1,556 -1,654 -1,748 -1,790 -1,896 -1,960
Accumulated Other Comprehensive Income / (Loss)		 -2.14 -0.87 -0.20 -0.02 -0.02 0.05 0.00 0.00 0.02 -0.00 -0.07

Annual Metrics And Ratios for Sana Biotechnology

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - 266,366,120.00
DEI Adjusted Shares Outstanding		 - - - - - - 266,366,120.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.92
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -99 -200 -250 -191 -205 -191 -175
Return On Investment Capital (ROIC_SIMPLE)		 - - - -29.33% -54.23% -57.47% -66.12%
Earnings before Interest and Taxes (EBIT)		 -141 -286 -357 -273 -293 -277 -250
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -139 -280 -346 -258 -269 -260 -238
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -220 -356 -275 -164 -197 -122
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 20 126 210 169 176 122
Increase / (Decrease) in Invested Capital		 0.00 20 106 84 -41 6.46 -53
Book Value per Share		 $0.00 ($32.36) $3.86 $2.62 $1.46 $1.12 $0.60
Tangible Book Value per Share		 $0.00 ($47.72) $2.80 $1.57 $0.44 $0.23 ($0.15)
Total Capital		 0.00 432 882 651 378 332 265
Total Debt		 0.00 0.00 153 151 91 82 104
Total Long-Term Debt		 0.00 0.00 102 96 91 82 64
Net Debt		 0.00 -412 -603 -289 -118 -75 -38
Capital Expenditures (CapEx)		 26 24 30 21 20 33 -0.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -25 -41 -42 -60 -41 -32
Debt-free Net Working Capital (DFNWC)		 0.00 353 510 388 149 115 110
Net Working Capital (NWC)		 0.00 353 459 333 149 115 70
Net Nonoperating Expense (NNE)		 32 85 106 79 78 76 69
Net Nonoperating Obligations (NNO)		 0.00 -412 -603 -289 -118 -75 -38
Total Depreciation and Amortization (D&A)		 1.83 5.92 11 16 25 17 13
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.14) ($1.43) ($1.46) ($1.16) ($0.96)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 189.54M 188.34M 194.54M 230.89M 253.23M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.14) ($1.43) ($1.46) ($1.16) ($0.96)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 189.54M 188.34M 194.54M 230.89M 253.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.14) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 166.43M 191.36M 220.45M 225.02M 266.87M
Normalized Net Operating Profit after Tax (NOPAT)		 -99 -200 -250 -191 -205 -191 -144
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Sana Biotechnology

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 266,366,120.00 266,866,897.00 278,291,590.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 266,366,120.00 266,866,897.00 278,291,590.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -0.22 -0.18 -0.23
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Growth		 -1.92% -33.95% 55.69% -2,329.91% 43.25% 56.32% -84.52% 31.62% - 2.06% 31.68%
EBIT Growth		 -10.44% -31.48% 54.03% -3,228.17% 44.02% 54.50% -76.43% 30.96% - 4.41% 31.38%
NOPAT Growth		 -10.80% -31.73% 57.54% -1,882.24% 43.87% 54.27% -92.37% 29.54% - 3.98% 31.12%
Net Income Growth		 -9.54% -30.87% 55.88% -6,189.84% 44.31% 54.05% -86.51% 29.66% - 4.41% 32.16%
EPS Growth		 -4.76% -13.95% 64.41% 0.00% 52.27% 57.14% -85.71% 36.00% - 19.05% 43.59%
Operating Cash Flow Growth		 31.69% 17.21% 0.44% 18.46% 9.23% 25.86% 43.46% 43.21% - 23.18% 0.94%
Free Cash Flow Firm Growth		 84.19% 95.03% 47.50% -271.47% -87.73% -560.51% 56.68% 193.27% - 127.23% -516.18%
Invested Capital Growth		 -19.50% -30.84% -4.92% -0.96% 3.81% 16.55% -32.06% -39.51% - -28.34% 19.24%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Q/Q Growth		 -3,127.66% -34.54% 53.54% -17.84% 22.95% -3.78% -95.84% 56.33% - 21.28% -36.62%
EBIT Q/Q Growth		 -4,725.29% -21.95% 51.59% -16.84% 18.84% 0.68% -87.33% 54.27% - 21.30% -34.47%
NOPAT Q/Q Growth		 -2,808.45% -22.19% 55.41% -25.09% 17.64% 0.46% -87.59% 54.18% - 20.56% -34.57%
Net Income Q/Q Growth		 -9,054.98% -21.97% 53.21% -19.15% 18.11% -0.65% -89.92% 55.06% - 19.75% -34.79%
EPS Q/Q Growth		 0.00% -11.36% 57.14% -19.05% 16.00% 0.00% -85.71% 58.97% - 15.00% -29.41%
Operating Cash Flow Q/Q Growth		 18.24% -26.32% 10.80% 11.48% 8.99% -3.17% 31.97% 11.09% - -14.52% 12.28%
Free Cash Flow Firm Q/Q Growth		 -192.51% 58.93% -178.37% -62.12% -1.28% -44.51% 81.74% 449.07% - 56.60% -513.16%
Invested Capital Q/Q Growth		 -4.21% -9.58% 12.79% 1.38% 0.41% 1.51% -34.26% -9.73% - 4.48% 9.39%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Tax Burden Percent		 99.95% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Interest Burden Percent		 97.29% 97.25% 94.01% 95.87% 96.74% 98.03% 99.39% 97.68% - 98.03% 98.26%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Equity (ROE)		 -72.00% -76.82% -70.51% -92.90% -99.17% -71.44% -109.12% -96.11% - -147.41% -152.87%
Cash Return on Invested Capital (CROIC)		 -86.46% -83.06% -94.85% -123.33% -114.34% -105.04% -86.44% -70.30% - -80.44% -136.59%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Common Equity (ROCE)		 -72.00% -76.82% -70.51% -92.90% -99.17% -71.44% -109.12% -96.11% - -147.41% -152.87%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -82.26% -72.10% -104.56% 0.00% -99.81% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -63 -78 -35 -43 -36 -35 -66 -30 -43 -34 -46
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -12.13% -13.98% -9.25% -10.90% -13.97% -11.04% -31.74% -11.31% - -120.31% -179.76%
Return On Investment Capital (ROIC_SIMPLE)		 -16.76% - - - -10.72% -12.33% -34.23% -11.57% -16.17% -14.59% -15.03%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -91 -111 -53 -63 -51 -50 -94 -43 -61 -48 -65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -79 -107 -50 -58 -45 -47 -92 -40 -58 -46 -63
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.80 5.88 3.56 3.16 1.45 1.81 5.02 4.32 - 6.45 6.28
Price to Tangible Book Value (P/TBV)		 9.17 12.57 8.65 9.99 7.18 40.84 0.00 0.00 - 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.05 12.94 6.04 4.61 1.65 1.95 5.20 7.13 - 6.08 6.84
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.32 0.25 0.26 0.29 0.33 0.37 0.58 0.35 - 0.96 0.97
Long-Term Debt to Equity		 0.32 0.25 0.26 0.29 0.33 0.37 0.58 0.35 - 0.51 0.38
Financial Leverage		 -0.52 -0.53 -0.49 -0.47 -0.36 -0.43 -0.37 -0.42 - -0.07 -0.07
Leverage Ratio		 1.76 1.78 1.91 1.81 1.98 1.93 2.12 2.04 - 2.49 2.86
Compound Leverage Factor		 1.72 1.73 1.79 1.73 1.92 1.89 2.11 1.99 - 2.45 2.81
Debt to Total Capital		 24.02% 19.85% 20.68% 22.62% 24.58% 27.25% 36.90% 25.79% - 48.88% 49.26%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 22.96% 29.81%
Long-Term Debt to Total Capital		 24.02% 19.85% 20.68% 22.62% 24.58% 27.25% 36.90% 25.79% - 25.92% 19.45%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 75.98% 80.15% 79.32% 77.38% 75.42% 72.75% 63.10% 74.21% - 51.12% 50.74%
Debt to EBITDA		 -0.34 -0.31 -0.39 -0.30 -0.31 -0.40 -0.30 -0.30 - -0.48 -0.72
Net Debt to EBITDA		 0.44 0.75 0.73 0.41 0.29 0.16 0.02 0.40 - -0.04 0.07
Long-Term Debt to EBITDA		 -0.34 -0.31 -0.39 -0.30 -0.31 -0.40 -0.30 -0.30 - -0.26 -0.28
Debt to NOPAT		 -0.44 -0.42 -0.50 -0.39 -0.43 -0.53 -0.40 -0.40 - -0.66 -0.98
Net Debt to NOPAT		 0.58 0.99 0.94 0.54 0.39 0.21 0.03 0.53 - -0.05 0.10
Long-Term Debt to NOPAT		 -0.44 -0.42 -0.50 -0.39 -0.43 -0.53 -0.40 -0.40 - -0.35 -0.39
Altman Z-Score		 -1.79 1.29 -0.66 -1.83 -3.67 -4.40 -5.92 -3.63 - -5.64 -4.62
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.31 6.07 5.20 4.47 3.54 3.40 2.47 4.55 - 1.29 1.38
Quick Ratio		 3.18 5.88 4.96 4.23 3.36 3.16 2.17 4.31 - 1.17 1.30
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -22 -9.20 -26 -42 -42 -61 -11 39 11 17 -68
Operating Cash Flow to CapEx		 -369.92% -414.21% -448.38% -1,266.04% -10,816.74% 0.00% 0.00% 0.00% - -93,447.50% -2,051.94%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 169 153 173 175 176 178 117 106 122 128 140
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Increase / (Decrease) in Invested Capital		 -41 -68 -8.94 -1.70 6.46 25 -55 -69 -53 -51 23
Enterprise Value (EV)		 686 1,982 1,042 808 289 347 611 755 - 777 957
Market Capitalization		 804 2,204 1,209 925 364 378 616 844 - 769 971
Book Value per Share		 $1.46 $1.70 $1.53 $1.31 $1.12 $0.93 $0.54 $0.82 $0.60 $0.45 $0.56
Tangible Book Value per Share		 $0.44 $0.80 $0.63 $0.42 $0.23 $0.04 ($0.34) ($0.02) ($0.15) ($0.30) ($0.16)
Total Capital		 378 468 428 378 332 287 194 263 265 233 305
Total Debt		 91 93 89 85 82 78 72 68 104 114 150
Total Long-Term Debt		 91 93 89 85 82 78 72 68 64 60 59
Net Debt		 -118 -222 -167 -117 -75 -31 -5.21 -89 -38 8.68 -15
Capital Expenditures (CapEx)		 14 16 13 4.09 0.44 -0.12 -0.49 -0.10 0.21 0.04 1.60
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -60 -47 -43 -40 -41 -29 -28 -31 -32 -26 -27
Debt-free Net Working Capital (DFNWC)		 149 268 213 163 115 80 49 126 110 79 138
Net Working Capital (NWC)		 149 268 213 163 115 80 49 126 70 25 47
Net Nonoperating Expense (NNE)		 25 30 16 17 13 14 27 12 16 13 18
Net Nonoperating Obligations (NNO)		 -118 -222 -167 -117 -75 -31 -5.21 -89 -38 8.68 -15
Total Depreciation and Amortization (D&A)		 11 3.75 3.90 4.06 5.69 3.65 2.86 3.19 3.05 2.39 2.23
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21) ($0.39) ($0.16) ($0.20) ($0.17) ($0.22)
Adjusted Weighted Average Basic Shares Outstanding		 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M 238.41M 260.49M 253.23M 276.86M 295.67M
Adjusted Diluted Earnings per Share		 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21) ($0.39) ($0.16) ($0.20) ($0.17) ($0.22)
Adjusted Weighted Average Diluted Shares Outstanding		 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M 238.41M 260.49M 253.23M 276.86M 295.67M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 220.45M 221.50M 222.47M 223.27M 225.02M 225.56M 237.81M 266.37M 266.87M 278.29M 299.36M
Normalized Net Operating Profit after Tax (NOPAT)		 -63 -78 -35 -43 -36 -35 -35 -30 -43 -34 -46
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Sana Biotechnology’s latest quarter shows a company with a strong cash position, but still a very large burn rate and no revenue. For retail investors, the big picture is that Sana remains a development-stage biotech: it is spending heavily on research, reporting recurring losses, and relying on its balance sheet and periodic capital raises to fund operations.

  • Cash and investments remain substantial: At the end of Q1 2026, Sana reported $83.8 million in cash and equivalents, $17.3 million in short-term investments, and $4.2 million in restricted cash, giving it meaningful near-term liquidity.
  • Liquidity improved sequentially: Total current assets rose to $111.7 million in Q1 2026 from $161.8 million in Q3 2025 and $82.5 million in Q2 2025, reflecting active balance sheet management and investment activity.
  • Operating cash outflow improved year over year: Net cash used in operating activities was $37.4 million in Q1 2026, better than $48.7 million in Q1 2025 and $47.2 million in Q4 2024.
  • Investing activity helped offset burn in Q1 2026: Sana generated $49.4 million of net cash from investing activities, mainly from sales and maturities of investments.
  • Financing dependence has been lower recently: Q1 2026 financing cash flow was nearly flat, with only a $128,000 net outflow, suggesting the quarter was funded more by existing resources than by new dilution.
  • R&D spending is down from prior periods: Research and development expense fell to $37.2 million in Q1 2026 from $49.0 million in Q4 2025 and $39.1 million in Q1 2025, which may indicate tighter cost control.
  • No revenue yet: Sana reported $0 in revenue in every quarter shown, so the investment case still depends on future clinical and pipeline progress rather than current sales.
  • Losses remain large: Q1 2026 net loss was $47.2 million, compared with a $58.8 million loss in Q4 2025 and $49.4 million in Q1 2025.
  • Shares outstanding have been creeping up over time: Basic weighted-average shares rose to 276.9 million in Q1 2026 from 237.6 million in Q1 2025, which can weigh on per-share value.
  • Balance sheet still carries sizable intangible and goodwill assets: Goodwill of $140.6 million and intangible assets of $59.2 million remain on the books, which can become a concern if future write-downs are needed.
  • Operating losses remain the core issue: Q1 2026 operating loss was $48.6 million, and Sana has posted repeated quarterly operating losses for several years.
  • Long-term liabilities are heavy: Total liabilities were $254.4 million in Q1 2026, including $60.5 million of capital lease obligations and $107.6 million of other noncurrent operating liabilities.
  • Equity has fallen sharply over the long term: Total common equity dropped to $119.2 million in Q1 2026 from $375.1 million in Q1 2024 and $428.3 million in Q1 2023, reflecting years of accumulated losses and financing activity.
  • Cash has trended lower from earlier levels: Cash and equivalents were $83.8 million in Q1 2026, down from $103.4 million in Q3 2025 and far below the $177.1 million reported in Q1 2024.
  • Historical cash burn has been significant: Sana used $65.6 million in operating cash flow in Q1 2024, $58.8 million in Q2 2024, and $51.8 million in Q3 2024, underscoring how capital-intensive the business remains.

Bottom line: Sana Biotechnology’s financial statements show a company with enough liquidity to keep advancing its pipeline in the near term, but with no revenue and ongoing losses, the stock still carries high execution and financing risk. Investors will likely need to see meaningful clinical progress, improving cost discipline, or a stronger funding runway before the fundamentals begin to look more durable.

08/25/26 02:49 PM ETAI Generated. May Contain Errors.

Sana Biotechnology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sana Biotechnology's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Sana Biotechnology's net income appears to be on an upward trend, with a most recent value of -$244.17 million in 2025, rising from -$130.78 million in 2019. The previous period was -$266.76 million in 2024. See where experts think Sana Biotechnology is headed by visiting Sana Biotechnology's forecast page.

Sana Biotechnology's total operating income in 2025 was -$250.32 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $250.32 million

Over the last 6 years, Sana Biotechnology's total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Sana Biotechnology's total liabilities were at $256.01 million at the end of 2025, a 2.2% increase from 2024, and a 14.3% decrease since 2020.

In the past 5 years, Sana Biotechnology's cash and equivalents has ranged from $71.87 million in 2025 to $253.03 million in 2021, and is currently $71.87 million as of their latest financial filing in 2025.

Over the last 6 years, Sana Biotechnology's book value per share changed from 0.00 in 2019 to 0.60 in 2025, a change of 60.4%.


Related Companies

Financial statements for NASDAQ:SANA last updated on 8/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel